Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42229426.
- Also identified by DOI 10.1016/j.xcrm.2026.102842.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic, drug-resistant bone infection caused by methicillin-resistant Staphylococcus aureus (MRSA) features an immunosuppressive niche enabling persistent infection and impaired bone healing. A specific treatment requires initial antibacterial immune activation against infection, followed by reshaping an anti-inflammatory microenvironment for later bone repair. Here, we screen Lactococcus lactis outer membrane vesicles (Lac-OMVs) with first-stage dendritic cell (DC) activation and later stage inflammatory macrophage repolarization potential. Mechanistically, enrichment of the nicotinamide metabolism pathway within Lac-OMVs is discovered, with nicotinamide adenine dinucleotide (NAD<sup>+</sup>) as a key anti-inflammatory mediator. NAD<sup>+</sup>-enriched Lac-OMVs (NAD<sup>+</sup>-Lac-OMVs) are thus metabolically engineered via targeted culture condition optimization, exerting biphasic immunomodulatory effects: (1) early-stage DC activation establishes robust humoral immunity, protecting against primary and recurrent MRSA challenge (99.35% and 98.07% bacterial clearance rates, respectively); and (2) later stage targeted NAD<sup>+</sup> delivery reprograms inflammatory macrophages at the defect site, resolving inflammation and establishing a pro-osteogenic microenvironment (∼10 times higher bone-repair rate).